BioWorld - Wednesday, February 18, 2026

IPO, Medical technology
IPO, Medical technology RSS Feed RSS

DNA with bar chart
Med-tech financings May 2024

Med-tech financings in May up more than 300% month-over-month

June 10, 2024
By Amanda Lanier
The med-tech industry has maintained its financing momentum into May, with the first five months of 2024 raising $12.7 billion, marking a 42% increase from $8.95 billion during the same period in 2023. Notably, May alone saw $5.05 billion in total med-tech financings, a 307% rise from $1.24 billion in April, and the highest monthly total reported by BioWorld MedTech since November 2022.
Read More
Businessman and IPO virtual screen

Telix announces $200M Nasdaq IPO to bolster radiopharma pipeline

June 7, 2024
By Tamra Sami
Australian radiopharmaceutical company Telix Pharmaceuticals Ltd. announced its IPO on the Nasdaq to raise $200 million to advance its late-stage radiopharma candidates. Headquartered in Melbourne, Telix has operations in the U.S., Europe (Belgium and Switzerland) and Japan with an extensive pipeline of theranostic radiopharmaceutical candidates.
Read More
Financial line graph
Med-tech financings March 2024

Med-tech financings continue to outpace last year

April 9, 2024
By Amanda Lanier
Top of FormMed-tech financings in March totaled $1.79 billion. Although a decline from February’s total, the cumulative value for the first three months of the year reached $6.02 billion, an increase from $4.69 billion during the same period the previous year.
Read More

Small gains, but gloomy US IPO market prevails

Feb. 28, 2024
By Mari Serebrov
“The market stinks,” Brian Johnson, a partner and vice chair of Wilmerhale’s corporate practice group, told a U.S. SEC advisory committee Feb. 27, as he painted a gloomy picture of last year’s IPO landscape in the U.S. While the scene was a little brighter than in 2022, a few key indicators could be worrisome, especially the median offering size, which is predictive of the strength of the IPO market, Johnson said
Read More
’23 in review

IPOs lead the 2023 downturn in med-tech financings

Dec. 28, 2023
By Amanda Lanier
Most categories of med-tech financings peaked during the COVID-19 pandemic, with the highest values seen in 2020-2021. While public/other and private financings have successfully rebounded to pre-pandemic levels, the aggregate financings for 2023 hit an unprecedented low according to BioWorld’s records.
Read More